- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04697784
Estudo pós-aprovação do sistema de endoprótese abdominal TREO (TREO PAS)
Estudo pós-aprovação do sistema de endoprótese abdominal TREO (P190015) em pacientes com aneurismas aórticos e aorto-ilíacos abdominais infrarrenais
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.
The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Vascular Surgery Specialists
-
Tucson, Arizona, Estados Unidos, 85718
- Pima Heart and Vascular
-
-
California
-
Fresno, California, Estados Unidos, 93701
- University of California, San Francisco-Fresno
-
La Jolla, California, Estados Unidos, 92037
- University of California, San Diego
-
San Diego, California, Estados Unidos, 92161
- VA San Diego
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Anschutz
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Medstar Washington Hospital Center
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- University of Florida
-
Gainesville, Florida, Estados Unidos, 32608
- Malcom Randall VA Medical Center
-
Pensacola, Florida, Estados Unidos, 32504
- Coastal Vascular and Interventional
-
Tampa, Florida, Estados Unidos, 33606
- University of South Florida / Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Northside Hospital
-
Atlanta, Georgia, Estados Unidos, 30309
- Piedmont Heart Institute
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Hospital and Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center
-
-
Michigan
-
Bay City, Michigan, Estados Unidos, 48708
- McLaren Bay Region
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Barnes Jewish Hospital at Washington University
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Rutgers Robert Wood Johnson Medical Center
-
-
New York
-
New York, New York, Estados Unidos, 10075
- Lenox Hill Hospital / Northwell Health
-
Stony Brook, New York, Estados Unidos, 11794-8191
- Stony Brook Medical Center
-
Syracuse, New York, Estados Unidos, 13210
- SUNY Upstate Medical University
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 27607
- Mission Health
-
Greenville, North Carolina, Estados Unidos, 27834
- East Carolina University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97239
- VA Portland Healthcare System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos, 37660
- Wellmont Cardiology Services
-
-
Texas
-
Austin, Texas, Estados Unidos, 78756
- St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132
- University of Utah Hospital
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 22042
- Sentara Heart Hospital
-
Richmond, Virginia, Estados Unidos, 23282
- Virginia Commonwealth University
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Willing and able to comply with all study procedures and visits.
- Written informed consent to participate in the study.
- Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
- Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.
Exclusion Criteria:
• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Subjects who receive the TREO Abdominal Stent-Graft System
Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System. |
The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
Prazo: Through 5 Years post-procedure
|
Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies. |
Through 5 Years post-procedure
|
|
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
Prazo: Through 5 Years post-procedure
|
Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies. |
Through 5 Years post-procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with technical success at the conclusion of the index procedure
Prazo: Through 5 Years post-procedure
|
Defined as the following:
|
Through 5 Years post-procedure
|
|
Major Adverse Events
Prazo: Through 5 Years post-procedure
|
Incidence of the following Major Adverse Events
|
Through 5 Years post-procedure
|
|
Incidence of procedure-related clinical utility measures
Prazo: Through 5 Years post-procedure
|
Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type. |
Through 5 Years post-procedure
|
|
Incidence of procedure-related complications
Prazo: Through 5 Years post-procedure
|
Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related. |
Through 5 Years post-procedure
|
|
Incidence of successful aneurysm treatment
Prazo: 12 months post-implant
|
Successful aneurysm treatment is defined as:
|
12 months post-implant
|
|
Incidence of all-cause mortality
Prazo: Through 5 Years post-procedure
|
Rate of mortality attributed to any causality as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm-related mortality
Prazo: Through 5 Years post-procedure
|
Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm rupture
Prazo: Through 5 Years post-procedure
|
Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of secondary interventions.
Prazo: Through 5 Years post-procedure
|
Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System |
Through 5 Years post-procedure
|
|
Incidence of conversion to open surgical repair.
Prazo: Through 5 Years post-procedure
|
Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft occlusion (i.e., loss of patency)
Prazo: Through 5 Years post-procedure
|
Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition. |
Through 5 Years post-procedure
|
|
Incidence of device stenosis or kink
Prazo: Through 5 Years post-procedure
|
Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of loss of device integrity
Prazo: Through 5 Years post-procedure
|
Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
Prazo: Through 5 Years post-procedure
|
Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
Prazo: Through 5 Years post-procedure
|
Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of Type I, II, III, IV or V Endoleaks
Prazo: Through 5 Years post-procedure
|
Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab. |
Through 5 Years post-procedure
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Gretchen Wild, Terumo Aortic
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IP-0021-20
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .